Chinese Fibromyalgia Market Share

Chinese Fibromyalgia Market Overview

Chinese Fibromyalgia Market Size was valued at USD 13.45 Billion in 2023. The Global Chinese Fibromyalgia industry is projected to grow from USD 13.93 Billion in 2024 to USD 21.53 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 14.32% during the forecast period (2024 - 2032).

Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used.  Other diagnostic procedures, such as laboratory evaluations are also used.

Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.

Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.

However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with an extensive product portfolio and pipeline, announced positive results from its clinical pharmacokinetic (PK) bridging study of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in healthy adult male and female ethnic Japanese and Chinese volunteers in February 2024.

A Sheffield woman who claimed to have perfect health after curing herself of chronic fatigue will appear on Dragons’ Den in January 2024. Giselle Boxer was working at one of the top advertising agencies when she was twenty-six years old; that is when M.E (myalgic encephalomyelitis) was diagnosed.

There has been massive research coverage and news about various aspects of fibromyalgia in China since July 2024. According to a recent cross-sectional study examining demography characteristics as well as clinical features among Chinese fibromyalgia patients, these studies concluded that fibromyalgia significantly affects the quality of life and is often accompanied by other health problems such as depression and chronic fatigue.

Intended Audience

• Pharmaceutical Companies


• Hospitals & Clinics


• Research and Development (R&D) Companies


• Government Research Institute


• Academic Institutes and Universities

Figure: Chinese Fibromyalgia Market by Diagnosis market share, 2016 (%)

Sources: Annual reports, Press release, White paper, Company presentation

Chinese Fibromyalgia Market Segmentat Insights

The chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the chinese fibromyalgia market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the chinese fibromyalgia market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the chinese fibromyalgia market is segmented into hospitals, clinics, diagnostic centers, and others.

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Key Findings

• The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%


• On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of 77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022


• On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022


• South Central China holds the largest share of the Chinese fibromyalgia market and is expected to reach USD 785.3 million by 2022


• North China is the fastest growing market, which is expected to grow at a CAGR of 19.2% over the forecast period 2017-2022

Chinese Fibromyalgia Market Regional Analysis

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.

Chinese Fibromyalgia Market Key Players

Some of key the players in the chinese fibromyalgia market are 

• Pfizer, 


• Roche, 


• Astellas Pharma, 


• Eli Lilly and Company, 


• Johnson & Johnson Services, Inc., 


• SANOFI, 


• Bayer AG, 


• GlaxoSmithKline, 


• AstraZeneca, 


• AbbVie, 


• ALLERGAN, 


• Boehringer Ingelheim, 


• Cephalon, Inc., 


• Vertical Pharmaceuticals, 


• Sunovion Pharms Inc, 


• Jazz Pharmaceuticals, 


• ABBOTT, 


• NOVARTIS, and 


• others.